AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03273751 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
Study NCT02739724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adnexal surgery
Study NCT02739724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adnexal surgery
Study NCT02831920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CEUS and targeted biopsies
Study NCT03135548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab (low dose)
Description: 12 weeks treatment
Study NCT03135548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks treatment
Study NCT03135548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab (high dose)
Description: 12 weeks treatment
Study NCT01712789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
Study NCT01712789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
Study NCT00072163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT00072163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study NCT04592133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Ultrasonography Examination
Study NCT00445055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Droperidol
Description: Intravenous injection
Study NCT00632034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD34+ haemopoietic stem cells
Description: Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
Study NCT00813956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine plus carboplatin plus BSI-201
Description: iv, 3 week cycles
Study NCT04254237 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraumbilical Hasson trocar incision
Description: Infraumbilical Hasson trocar incision
Study NCT02246374 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ExAblate Transcranial System
Description: ExAblate Transcranial System subthalamotomy for symptoms of Parkinson's Disease
Study NCT02246374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial System
Description: ExAblate Transcranial System subthalamotomy for symptoms of Parkinson's Disease
Study NCT03891680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Injectable Product
Description: Intra articular Botox injection
Study NCT03891680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequancy
Description: Genicular nerves radiofrequancy
Study NCT04254237 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Supraumbilical Hasson trocar incision
Description: Supraumbilical Hasson trocar incision
Study NCT03434132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or robotic radical cystectomy
Description: ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed.
Study NCT03434132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open or robotic radical cystectomy
Description: ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed.
Study NCT01797432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
Description: Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
Study NCT01797432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane
Description: Intralesional injections of 2mLs of Restylane on one side of the scalp
Study NCT01693939 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FS200 Femtosecond Laser
Study NCT02967211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (U300)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02967211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine (U100)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02967211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02967211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02967211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT01850966 — intervention group
Intervention type: DRUG
Intervention: Iguratimod
Description: The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.
Study NCT02216422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/Paritaprevir/Ritonavir
Description: Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
Study NCT02216422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: Tablet
Study NCT02216422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet
Study NCT01325987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Subjects with vitamin D deficiency (serum 25(OH)D \<20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
Study NCT01325987 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 1. group: vitamin D2 50000 IU weekly once for 8 weeks~2. nd group: placebo weekly once for 8 weeks
Study NCT02341534 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BioMonitor
Description: Patients will be implanted with the BioMonitor + Home Monitoring feature
Study NCT02677103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial extracorporeal shock wave therapy
Description: he RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder.
Study NCT02677103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided needle puncture
Description: After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed.
Study NCT02677103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RSWT and USNP
Description: each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs.
Study NCT03504865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Given at the end of the operation.
Study NCT03504865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard bupivacaine
Description: Given at the end of the operation.
Study NCT03504865 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be administered as the placebo and will be given at the end of the operation.
Study NCT02460744 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Description: Radiation dose of 34Gy in 10 fractions over 2 weeks.
Study NCT03023332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training
Description: A cognitive-behavioral intervention delivered through iPad technology that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
Study NCT03023332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Description: Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and continue to influence behavior.
Study NCT03023332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bipolar Education
Description: An educational program designed to teach family caregivers of about the types, causes, symptoms, episodes, warning signs, and treatments for individuals with bipolar disorder, as well as available resources for assisting a family member with bipolar disorder. The content to be presented within an audiovisual format using iPad technology follows the recommendations and guidelines developed through research and by the Depression and Bipolar Support Alliance and the National Institute of Mental Health.
Study NCT03023332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Education
Description: An educational program designed to teach family caregivers of about the types, causes, symptoms, episodes, warning signs, and treatments for individuals with bipolar disorder, as well as available resources for assisting a family member with bipolar disorder. The content to be presented within an audiovisual format using iPad technology follows the recommendations and guidelines developed through research and by the Depression and Bipolar Support Alliance and the National Institute of Mental Health.
Study NCT00747981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic CT Scan
Description: Perform a CT Scan and an endoscopy
Study NCT02986828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
Study NCT02986828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.
Study NCT02986828 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study NCT03596983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Week 2 Intervention
Description: * Sleep Diaries (Daily)~* Phone Calls (weekly with study team)~* Wrist Accelerometry and fitbit 24/7 for 14 days~* SAFTEE Questionnaire~* ASA24~* Behavioral risk factor surveillance system (smoking and alcohol use questions)~* Psychological well-being (SF36)~* Index of Self Regulation~* PROMIS fatigue scale-morning (weekly)~* PROMIS fatigue scale-evening (weekly)~* Epworth Sleepiness Scale (weekly)
Study NCT04503642 — intervention group
Intervention type: PROCEDURE
Intervention: Changing the surgical team for wound closure
Description: The intervention consists of the exchange of the primary surgical team with a second surgical team that consists of one surgeon and one student. The first surgical team then may leave the operation theatre but is continuously accessible for questions.
Study NCT02986828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT03066388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse pressure variations
Description: Stroke volume and, pulse pressure variations obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin.
Study NCT03533491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rewire App
Description: A prototype Rewire app will be designed and created; the first four modules will be evaluated by 60 high-risk adolescents. The teens are asked to complete each module and spend a few minutes each day for two weeks using the practice exercises.
Study NCT03731585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in psychological sessions
Study NCT03731585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in educational sessions
Study NCT03731585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03731585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Participate in group sessions
Study NCT03702738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: NAC is listed by WHO as an essential medicine for its use in paracetamol (acetaminophen) poisoning, in which it protects against fatal liver injury. It also reduces the viscosity of sputum, thereby serving as an expectorant.
Study NCT03964909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging
Description: Undergo fMRI
Study NCT03964909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo CVR MRI
Study NCT03964909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resting State Functional Connectivity Magnetic Resonance Imaging
Description: Undergo rs-fMRI
Study NCT03912753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comunică
Description: Comunică is based on the Information-Motivation-Behavioral Skills (IMB) model of health behavior change, which postulates that individuals must possess the requisite information for enacting sexual health, motivation to change their HIV risk and alcohol use, and behavioral skills necessary for reducing their risk. Therefore, Comunică includes MI to provide accurate information about HIV transmission, alcohol abuse, and local GBM-affirmative health resources and build motivation to improve behavioral skills (via CBST). CBST is a therapeutic approach used in the treatment of various behavioral problems, such as alcohol abuse and depression and more recently HIV risk. CBST can help modify cognitions driving unhealthy behaviors, promote awareness of contextual triggers and unhealthy behavioral patterns, and teach coping skills to improve health. Comunică also draws upon minority stress theory recognizing that stigmatizing societal contexts compromise health behavior.
Study NCT03912753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Attention Control
Description: The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.
Study NCT02025205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial Valve
Description: Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
Study NCT04575675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10mg once daily
Study NCT04575675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Sacubitril-Valsartan, maximal tolerated dosage
Study NCT04575675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sacubitril-Valsartan
Description: Sacubitril-Valsartan, maximal tolerated dosage
Study NCT02831920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI and targeted biopsies
Study NCT02364531 — intervention group
Intervention type: OTHER
Intervention: Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry
Description: Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
Study NCT04168307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle trainer device
Description: The ankle trainer provides passive stretch in dorsal flexion of the ankle as well as active plantar flexion.
Study NCT04168307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: The patients were instructed in stretching exercises using a non-elastic band
Study NCT02611362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB Gaming Intervention
Study NCT04575675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol
Study NCT03567499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.
Study NCT04575675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beta blocker
Description: Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol
Study NCT04575675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid Receptor Antagonist
Description: Mineralocorticoid receptor antagonist, including spironolactone or eplerenone
Study NCT04575675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mineralocorticoid Receptor Antagonist
Description: Mineralocorticoid receptor antagonist, including spironolactone or eplerenone
Study NCT04575675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy and/or implantable cardioverter defibrillator
Description: CRT-P, CRT-D or ICD if clinically indicated
Study NCT04575675 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac resynchronization therapy and/or implantable cardioverter defibrillator
Description: CRT-P, CRT-D or ICD if clinically indicated
Study NCT01782326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
Study NCT01782326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
Description: Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
Study NCT01720017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preclinical Manikin Training
Description: During the preclinical manikin training, each subject will perform 10 intubations in a manikin with a difficult airway simulated by swelling the manikin tongue and placing it in a cervical collar.
Study NCT01720017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inservice Training
Description: Inservice training will include review of a product information handout and a video demonstration.
Study NCT04437771 — intervention group
Intervention type: OTHER
Intervention: Safety and efficacy assessments
Description: Long term disease and gene therapy specific safety evaluations and efficacy assessments
Study NCT02298543 — intervention group
Intervention type: OTHER
Intervention: coronary spasm